Calmodulin inhibitors activate glycogen phosphorylase B to A conversion in C6 glioma cells.
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002135:Calcium-Binding Proteins / Q000037:antagonists & inhibitors*; D002147:Calmodulin / Q000037:antagonists & inhibitors* / Q000502:physiology; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000032:analysis; D004789:Enzyme Activation; D005910:Glioma / Q000201:enzymology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D006005:Phosphorylases / Q000378:metabolism*; D051381:Rats
D014150:Antipsychotic Agents; D002135:Calcium-Binding Proteins; D002147:Calmodulin; D010726:Phosphodiesterase Inhibitors; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D000001:Calcimycin; D000242:Cyclic AMP; D006005:Phosphorylases; D002118:Calcium; D015056:1-Methyl-3-isobutylxanthine